News

Veryan Medical and Vasorum Ltd. enter distribution agreement for Celt ACD Vascular Closure Device

August 3, 2020
Vasorum (Dublin, Ireland) and Veryan Medical (Horsham, UK) have announced that from today Veryan Medical will support Vasorum in the commercialization of the Celt ACD in the USA. The Celt ACD, is an Arterial Closure Device that has been used in more than 60,000 patients to date with excellent clinical results following percutaneous catheter-based vascular procedures. Vasorum co-founder and CEO, Jim Coleman MD said, “The Veryan Medical agreement is validation that the Celt ACD has proven itself to be a leading arterial closure device that allows rapid and complete hemostasis independent of vascular anatomy, including calcified arteries. This agreement provides an opportunity to accelerate growth for both companies in the USA. “… View Article
Read more...

Vasorum Launches Celt ACD Second Generation Vascular Closure Device in the USA

July 11, 2019
DUBLIN, Ireland, September 12, 2017 /PRNewswire/ —Vasorum Ltd, following FDA approval of its PMA supplement, the developer and manufacturer of the novel Celt ACD vascular closure device has added a 7F sized Celt ACD device to its Celt ACD 6F and Celt ACD 5F size range in the USA. Celt ACD is indicated for arterial puncture closure in both diagnostic and interventional cardiology and radiology patients. Celt ACD offers excellent time to hemostasis in a wide variety of clinical situations. The second generation Celt ACD devices now available in both the USA and Europe have a new improved delivery system which has been designed to enhance the user experience during deployment. The… View Article
Read more...

Vasorum Ltd. Receives FDA Approval for Celt ACD Vascular Closure Device

July 21, 2016
DUBLIN, July 21, 2016 /PRNewswire/ —Vasorum Ltd. The developer and manufacturer of the novel Celt ACD vascular closure device has received approval of its PMA application from the US Food and Drug Administration (FDA). Celt ACD, which previously received CE mark and is sold in Europe, is indicated for arterial puncture closure in both diagnostic and anticoagulated percutaneous interventional cardiology and radiology patients. Celt ACD offers excellent time to hemostasis in a wide variety of clinical situations. A randomized controlled clinical trial which recruited 207 interventional cardiology procedure patients was carried out in four International Cardiology Centres across US and Europe. The trial’s Principal Investigator was Dr. Shing-Chiu Wong, Director of Cardiac… View Article
Read more...